Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Mocci · SciRah

Researcher profile · Semantic Scholar

G. Mocci

Share profile

G. Mocci — researcher profile on SciRah

h-index: 21
Works: 195
Citations: 1,640

Most-cited papers

An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors
S. Onali, D. Pugliese, F. Caprioli, A. Orlando +26 more
2022American Journal of Gastroenterology52 citations Open access
Semantic Scholar
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study
D. Pugliese, G. Privitera, F. Crispino, N. Mezzina +56 more
2022Alimentary Pharmacology and Therapeutics42 citations Open access
Semantic Scholar
COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients’ Association
A. Costantino, D. Noviello, F. Conforti, M. Aloi +14 more
2021Inflammatory Bowel Diseases33 citations Open access
Semantic Scholar
Comparison of Performances of Adalimumab Biosimilars SB5, APB501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
A. Tursi, G. Mocci, L. Allegretta, G. Aragona +46 more
2022Inflammatory Bowel Diseases29 citations
Semantic Scholar
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients
A. Tursi, G. Mocci, R. Lorenzetti, L. Allegretta +25 more
2021European Journal of Gastroenterology and Hepathology28 citations
Semantic Scholar
Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study.
A. Tursi, G. Mocci, A. Cuomo, L. Allegretta +38 more
2021European Review for Medical and Pharmacological Sciences19 citations
Semantic Scholar
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.
A. Tursi, G. Mocci, A. Cuomo, A. Ferronato +46 more
2022Journal of Gastrointestinal and Liver Diseases15 citations Open access
Semantic Scholar
Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus.
G. Fiorino, F. Caprioli, S. Onali, F. Macaluso +33 more
2025Digestive and Liver Disease14 citations
Semantic Scholar
Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms
G. Mocci, A. Tursi, F. Onidi, P. Usai-Satta +2 more
2024Journal of Clinical Medicine13 citations Open access
Semantic Scholar
FODMAP Diet in Celiac Disease and Gluten-Related Disorders
Paolo Usai Satta, G. Mocci, Mariantonia Lai
2024Nutrients12 citations Open access
Semantic Scholar
Enhancing Oral 5-ASA Effectiveness in Mild-to-Moderate Ulcerative Colitis through an H. erinaceus-Based Nutraceutical Add-on Multi-Compound: The “HERICIUM-UC” Two-Arm Multicentre Retrospective Study
A. Tursi, A. D’Avino, Giovanni Brandimarte, G. Mocci +3 more
2024Pharmaceutics12 citations Open access
Semantic Scholar
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study
Antonio Tursi, G. Mocci, F. Scaldaferri, D. Napolitano +59 more
2024Expert Opinion on Biological Therapy11 citations
Semantic Scholar
Long-Term Effectiveness and Safety of Ustekinumab in Crohn’s Disease: Results from a Large Real-Life Cohort Study
G. Mocci, A. Tursi, F. Scaldaferri, D. Napolitano +80 more
2024Journal of Clinical Medicine11 citations Open access
Semantic Scholar
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study
A. Tursi, G. Mocci, L. Cingolani, E. Savarino +48 more
2023Expert Opinion on Pharmacotherapy11 citations
Semantic Scholar
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study
G. Mocci, A. Tursi, G. Maconi, G. Cataletti +60 more
2023Expert Opinion on Biological Therapy11 citations
Semantic Scholar
Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
G. Mocci, G. Bodini, L. Allegretta, A. Cazzato +12 more
2022Biomedicines11 citations Open access
Semantic Scholar
Review article: safety of new biologic agents for inflammatory bowel disease in the liver.
S. Magrì, L. Chessa, M. Demurtas, F. Cabras +1 more
2021European Journal of Gastroenterology and Hepathology11 citations
Semantic Scholar
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study
F. Scaldaferri, F. di Vincenzo, M. Aloi, M. Ascolani +49 more
2026American Journal of Gastroenterology9 citations Open access
Semantic Scholar
Lack of association between common polymorphisms associated with successful aging and longevity in the population of Sardinian Blue Zone
A. Errigo, M. P. Dore, G. Mocci, G. Pes
2024Scientific Reports9 citations
Semantic Scholar
Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies
A. Tursi, G. Mocci, A. Del Gaudio, Alfredo Papa
2024Expert Opinion on Biological Therapy8 citations
Semantic Scholar
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study
A. Papa, F. Scaldaferri, M. Covino, A. Tursi +20 more
2022Biomedicines8 citations Open access
Semantic Scholar
IBD impact on quality of life and perception of disease activity in Italian patients and physicians: An IBD-PODCAST study sub analysis.
E. Savarino, F. Caprioli, D. Ribaldone, S. Onali +18 more
2025Digestive and Liver Disease7 citations Open access
Semantic Scholar
EFFECT OF USTEKINUMAB ON EXTRAINTESTINAL DISEASES IN REFRACTORY CROHN'S DISEASE.
A. Tursi, G. Mocci, G. Maconi
2021Journal of Crohn's & Colitis7 citations
Semantic Scholar
Letter: ustekinumab for the treatment of post‐surgical and refractory Crohn's disease
A. Tursi, G. Mocci, M. Picchio, W. Elisei +1 more
2021Alimentary Pharmacology and Therapeutics6 citations Open access
Semantic Scholar
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE study.
D. Pugliese, G. Privitera, N. Cersullo, Harsh Bordekar +58 more
2025Digestive and Liver Disease5 citations
Semantic Scholar
Collagenous Sprue and Olmesartan: another pathological condition related to this drug.
R. Del Sordo, V. Villanacci, Arianna Oberti, D. Moneghini +1 more
2021Digestive and Liver Disease5 citations
Semantic Scholar
Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with Golimumab.
A. Tursi, G. Mocci, W. Elisei, L. Allegretta +19 more
2021Journal of Gastrointestinal and Liver Diseases5 citations Open access
Semantic Scholar
Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST Study.
E. Calabrese, S. Onali, A. Variola, D. Ribaldone +18 more
2024Digestive and Liver Disease4 citations Open access
Semantic Scholar
Adherence to clinical and endoscopic standards of quality in inflammatory bowel disease: a nationwide survey from the Italian Association of Hospital Gastroenterologists and Endoscopists.
M. D. Di Paolo, Andrea Cassinotti, Cristiano Pagnini, L. Ceccarelli +10 more
2025European Journal of Gastroenterology and Hepathology3 citations
Semantic Scholar
Non-Adherence Rate to Oral Mesalamine in Ulcerative Colitis Patients: A Systematic Review with Meta-Analysis
C. Pagnini, E. Antonelli, B. Scrivo, Maria Cappello +4 more
2025Journal of Personalized Medicine3 citations Open access
Semantic Scholar
P398 Long term efficacy and safety of ABP, 501 adalimumab biosimilar in inflammatory bowel diseases: preliminary results from the ADASWITCH study
A. Cingolani, C. Felice, G. Lombardi, F. Onidi +11 more
2022Journal of Crohn's & Colitis3 citations
Semantic Scholar
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy
A. Tursi, G. Mocci, L. Allegretta, G. Aragona +51 more
2021Expert Opinion on Biological Therapy3 citations
Semantic Scholar
DOP34 Long-term outcome of Acute Severe Ulcerative Colitis responsive to intravenous steroid: A multicenter study of the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
S. Festa, M. Scribano, A. Aratari, C. Bezzio +13 more
20213 citations
Semantic Scholar
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC).
D. Noviello, W. Fries, A. Orlando, F. Conforti +31 more
2025Digestive and Liver Disease2 citations Open access
Semantic Scholar
Sex-Specific Real-Life Profiling in Vedolizumab, Ustekinumab, and Tofacitinib Effectiveness in Ulcerative Colitis
A. Tursi, R. Pellegrino, G. Mocci, E. Savarino +3 more
2025Journal of Clinical Medicine2 citations
Semantic Scholar
Clinical Predictive Factors for the Development of Short Bowel Syndrome in a Cohort of Patients with Crohn’s Disease: A Prospective Study
L. Parisio, A. Del Gaudio, Jacopo Iaccarino, P. Puca +19 more
2025Journal of Clinical Medicine2 citations
Semantic Scholar
DOP101 Maintaining remission after an episode of steroid-responsive Acute Severe Ulcerative Colitis: what is the best strategy?
C. Bravo, C. Frias-Gomes, A. Blesl, J. Damasceno +36 more
2025Journal of Crohn's & Colitis2 citations Open access
Semantic Scholar
Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study
A. Tursi, G. Mocci, F. Costa, L. Ceccarelli +53 more
2025Intestinal Research2 citations Open access
Semantic Scholar
Impact of a Symbiotic Mixture on Moderate-to-severe Diverticular Disease of the Colon.
A. Tursi, G. Mocci, Paolo Usai Satta, W. Elisei
2024Reviews on recent clinical trials2 citations
Semantic Scholar
Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis—Where we are now in real life
G. Mocci, A. Tursi
2024Alimentary Pharmacology and Therapeutics2 citations Open access
Semantic Scholar
Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists
O. Nardone, G. Marasco, L. Lopetuso, G. Mocci +3 more
2023Journal of Clinical Medicine2 citations Open access
Semantic Scholar
Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason
G. Mocci, A. Cingolani, G. Orrù, C. Felice +12 more
2023Frontiers in Gastroenterology2 citations Open access
Semantic Scholar
P0598 MIRACLE-UC: Mirikizumab Investigation of Real-world Assessment of Clinical and Long-term Effectiveness and Adverse Events in Patients with Ulcerative Colitis - A Multicenter Prospective Study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).
B. Barberio, A. Todeschini, L. Laterza, A. Viola +36 more
2026Journal of Crohn's & Colitis1 citations
Semantic Scholar
DOP082 Real-world effectiveness and safety of three JAK inhibitors for ulcerative colitis: an IPTW analysis from IN-IBD
G. Mocci, A. Pasta, W. Elisei, B. Barberio +11 more
2026Journal of Crohn's & Colitis1 citations
Semantic Scholar
Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).
B. Barberio, F. D'Amico, L. Laterza, C. Bezzio +40 more
2026Alimentary Pharmacology and Therapeutics1 citations Open access
Semantic Scholar
P0634 Upadacitinib Effectiveness And Safety In Patients With Ulcerative Colitis: Data From A Real-World Study
G. Mocci, F. Scaldaferri, D. Napoltitano, D. Pugliese +36 more
2025Journal of Crohn's & Colitis1 citations
Semantic Scholar
Management of Post-Colonoscopy Syndrome with a Nutraceutical Intervention Based on Hericium erinaceus: A Retrospective Two-Arm Multicentre Analysis
A. Tursi, A. D’Avino, Giovanni Brandimarte, G. Mocci +4 more
2025Nutrients1 citations
Semantic Scholar
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class.
T. Innocenti, J. Hanžel, M. Truyens, Milan Lukáš +43 more
2025Journal of Crohn's & Colitis1 citations Open access
Semantic Scholar
P0587 Effectiveness and safety of Risankizumab in Crohn’s disease patients from a large Italian cohort: preliminary results from the RESOLVE IgIBD study
F. Scaldaferri, F. di Vincenzo, M. Allocca, M. Aloi +29 more
2025Journal of Crohn's & Colitis1 citations
Semantic Scholar
P1127 Diagnostic delay and economic burden in IBD: a multicenter italian experience in patients treated with biologics
G. Mocci, G. Orrù, F. Onidi, G. Bodini +8 more
2024Journal of Crohn's & Colitis1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Pugliese×18
Invite
D. Pugliese — researcher profile on SciRah
A. Ferronato×16
Invite
A. Ferronato — researcher profile on SciRah
M. Picchio×15
Invite
M. Picchio — researcher profile on SciRah
D. Ribaldone×14
Invite
D. Ribaldone — researcher profile on SciRah

×14

Invite

S. Rodino — researcher profile on SciRah

Invite

R. Colucci — researcher profile on SciRah

Invite

A. Tursi — researcher profile on SciRah

E. Savarino×12

Invite

E. Savarino — researcher profile on SciRah

Invite

A. Tursi — researcher profile on SciRah

L. Allegretta×12

Invite

L. Allegretta — researcher profile on SciRah

C. Zampaletta×12

Invite

C. Zampaletta — researcher profile on SciRah

Invite

W. Elisei — researcher profile on SciRah